LVTX: Lava Tx Net earnings per share (EPS TTM)

LAVA Therapeutics (LVTX) - corporate logo

Exclusive patents and stringent FDA control serve as the primary drivers for LAVA Therapeutics N.V. (LVTX), as confirmed by the 12-month net income per share snapshot. Meanwhile, -0.85 represents the current value of this metric. The company's prospects depend on the success of bispecific antibodies in the absence of revenue, although aggressive hiring of leading immunologists and a stock option system minimize personnel risks.

LVTX LAVA Therapeutics N.V. Net earnings per share for the last 12 months (07/04/2022 - 12/06/2025)

Summary analytical data breakdowns for LAVA Therapeutics N.V. (LVTX)

- share price and expert price forecast:
Fundamental valuation:LVTX - lavatherapeutics.com
Flagship merchandise of Lava Tx

EPS (TTM) reflects the net income allocated per share over a trailing twelve-month period. This metric allows for an assessment of the business's actual profitability by excluding the impact of the total share issuance. For LAVA Therapeutics N.V. (LVTX), with its complex molecular engineering and protected patents, this indicator is critical. By analyzing the EPS trend over 12 months, an investor can discern the monetization rates of bispecific antibodies. The trajectory of this curve determines the asset's fair value.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)